Cited by 453Nanoplatforms for cancer theranosticsPhotodynamic Therapy Research StudiesCancer Immunotherapy and Biomarkers

Phototherapy in cancer treatment: strategies and challenges

Open access
Cai, Yeyu, Chai, Tian, Nguyen, William, Liu, Jiayi, Xiao, Enhua, Ran, Xin, Ran, Yuping, Du, Dan +2 more·2025·Signal Transduction and Targeted Therapy

Abstract

Phototherapy has emerged as a promising modality in cancer treatment, garnering considerable attention for its minimal side effects, exceptional spatial selectivity, and optimal preservation of normal tissue function. This innovative approach primarily encompasses three distinct paradigms: Photodynamic Therapy (PDT), Photothermal Therapy (PTT), and Photoimmunotherapy (PIT). Each of these modalities exerts its antitumor effects through unique mechanisms—specifically, the generation of reactive oxygen species (ROS), heat, and immune responses, respectively. However, significant challenges impede the advancement and clinical application of phototherapy. These include inadequate ROS production rates, subpar photothermal conversion efficiency, difficulties in tumor targeting, and unfavorable physicochemical properties inherent to traditional phototherapeutic agents (PTs). Additionally, the hypoxic microenvironment typical of tumors complicates therapeutic efficacy due to limited agent penetration in deep-seated lesions. To address these limitations, ongoing research is fervently exploring innovative solutions. The unique advantages offered by nano-PTs and nanocarrier systems aim to enhance traditional approaches’ effectiveness. Strategies such as generating oxygen in situ within tumors or inhibiting mitochondrial respiration while targeting the HIF-1α pathway may alleviate tumor hypoxia. Moreover, utilizing self-luminescent materials, near-infrared excitation sources, non-photoactivated sensitizers, and wireless light delivery systems can improve light penetration. Furthermore, integrating immunoadjuvants and modulating immunosuppressive cell populations while deploying immune checkpoint inhibitors holds promise for enhancing immunogenic cell death through PIT. This review seeks to elucidate the fundamental principles and biological implications of phototherapy while discussing dominant mechanisms and advanced strategies designed to overcome existing challenges—ultimately illuminating pathways for future research aimed at amplifying this intervention’s therapeutic efficacy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41392-025-02140-y

Cites

611 of 611 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Most existing PSs are limited by excitation in tissue penetration-restricted regions, low ROS yields, and the absence of real-time therapeutic monitoring.

    “Moreover, most existing PSs are limited by excitation in tissue penetration-restricted regions, low ROS yields, and the absence of real-time therapeutic monitoring226.”

    From Organic small-molecule NIR-II fluorophores for tumor phototheranostics (2026) · cites this paper as [226]

    The Introduction (page unavailable) says that limited light penetration and factors including tumor hypoxia and photosensitizer quenching hinder ROS production in PDT. This supports the penetration and ROS parts of the claim, but the passages found do not establish that most existing photosensitizers lack real-time therapeutic monitoring. (LLM, conf=0.86)

    Experimental — accuracy not yet measured
  • Hyperthermia (HT), although rarely used as a primary treatment, can enhance the selectivity and efficacy of chemotherapy or radiotherapy by inducing heat shock protein (HSP) expression and modulating the TME.

    “Furthermore, hyperthermia (HT), although rarely used as a primary treatment, can enhance the selectivity and efficacy of chemotherapy or radiotherapy by inducing heat shock protein (HSP) expression and modulating the TME226.”

    From Organic small-molecule NIR-II fluorophores for tumor phototheranostics (2026) · cites this paper as [226]

    In “Principles of phototherapy” (page unavailable), the paper says low-to-moderate photothermal heating may activate HSPs and enhance the selectivity and efficacy of chemotherapy or radiotherapy by altering tumor perfusion and metabolic status. It does not establish that hyperthermia is rarely used as a primary treatment, and its account is specific to heating at approximately 41–43 °C rather than hyperthermia generally. (LLM, conf=0.86)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

1 retracted

Flagged first, then by citations

Research works printed but not linked: 2

  1. [278]Chudal, L. et al. Copper-cysteamine nanoparticles as a heterogeneous Fenton-like catalyst for highly selective cancer treatment. ACS Appl Bio Mater. 3, 1804–1814 (2020). 35021670 · DOI
  2. [309]Zhao, Y., Sultan, D. & Liu, Y. in Theranostic Bionanomaterials 27–53 (Elsevier, 2019).

Cited by

Sorted by citations

Authors
Cai, Y., Chai, T., Nguyen, W., Liu, J., Xiao, E., Ran, X., Ran, Y., Du, D., Chen, W., & Chen, X.
Affiliations
  • Second Xiangya Hospital of Central South University (CN)
  • Tang Du Hospital (CN)
  • Xi’an Jiaotong-Liverpool University (CN)
  • Sichuan University (CN)
Corresponding author
  • Chen, Wei
  • Chen, Xiangyu
Venue
Signal Transduction and Targeted Therapy
Published
2025-04-02
Volume
10
Issue
1
Pages
115-115
ISSN
2059-3635 (ISSN-L)
OpenAlex
W4409119844
Cited by
453
References
611
Citations by year
2026: 319 · 2025: 134
FWCI
36.48
Type
journal article
Language
en
Open access
Locations
  • Signal Transduction and Targeted Therapy (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Photodynamic Therapy Research Studies
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Keywords
phototherapy, photodynamic therapy, photothermal therapy, photoimmunotherapy, reactive oxygen species, tumor hypoxia, photothermal conversion efficiency, tumor targeting, nanocarriers, HIF-1α pathway, mitochondrial respiration inhibition, near-infrared excitation, immunoadjuvant, immunosuppressive cells, immune checkpoint inhibitors, immunogenic cell death, antitumor immunity
MeSH terms
Photothermal Therapy, Animals, Humans, Immunotherapy, Neoplasms, Photochemotherapy, Phototherapy, Photosensitizing Agents, Reactive Oxygen Species, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review